人肺鳞癌组织中Caveolin-1的表达及预后意义

  目的   研究Caveolin-1在人肺鳞癌中的表达, 探讨Caveolin-1的表达与人肺鳞癌临床病理特征以及预后的关系。   方法   运用免疫组织化学法检测人肺鳞癌组织中Caveolin-1、PCNA的表达, 并结合患者的临床病理特征和生存情况进行分析。   结果   Caveolin-1在人肺鳞癌中阳性率显著低于正常肺组织(P < 0.001);Caveolin-1的表达与肺鳞癌的TNM分期(P=0.018) 及淋巴结状态(P=0.006) 有关。在人肺鳞癌组织中Caveolin-1与PCNA表达呈正相关(r=0.360, P=0.018)。生存分析显示肺鳞癌中Caveolin-1阳性组的生存时间显著低于阴性组(P=0.007), 在24例淋巴结未转移组中Caveolin-1阳性组的生存时间显著低于阴性组(P=0.002)。多因素Cox分析显示Caveolin-1阳性表达、高临床分期、支气管残端有癌残留的肺鳞癌患者术后生存时间较短。   结论   Caveolin-1的表达与肺鳞癌的恶性演进呈正相关; 其可促进肺癌细胞的增殖。Caveolin-1可作为评估肺鳞癌患者的不良预后指标。 

Expression of Caveolin-1 and its significance in the prognosis of lung squamous cell carcinoma

  Objective   This study aims to examine caveolin-1 expression in lung squamous cell carcinoma (LSCC), to investigate the relationship of caveolin-1 expression with clinicopathological features, and to estimate the prognostic value of caveolin-1.   Methods   Immunohistochemical staining was used to determine caveolin-1 and PCNA expression in LSCC.The correlation among caveolin-1 expression, pathological features, and clinical outcomes were investigated.   Results   The positive rate of caveolin-1 protein was significantly lower in LSCC than in normal lung tissues (P < 0.001).Caveolin-1 expression was statistically correlated with the TNM stage (P=0.018) and lymph node metastasis (P=0.006).Caveolin-1 expression was also positively correlated with PCNA expression in LSCC (r=0.360;P=0.018).The Kaplan–Meier survival curve showed that patients with positive caveolin-1 expression had a significantly shorter survival time compared with the patients with negative expression (P=0.007).The caveolin-1-positive group had a significantly shorter survival time in 24 patients without lymph node metastasis compared with the negative group (P=0.002).Cox multivariate analysis revealed that patients with caveolin-1 positive expression, high TNM stage, and positive surgical margin had a significantly unfavorable prognosis.   Conclusion   Caveolin-1 expression is positively correlated with LSSC development as well as progression, and may promote tumor cell proliferation.Caveolin-1 may be used as a poor prognosis marker of LSCC.